Detalles de la búsqueda
1.
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Br J Haematol
; 204(2): 525-533, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37905734
2.
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells.
Br J Haematol
; 2024 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38894496
3.
Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis.
Cytotherapy
; 26(1): 73-80, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37952139
4.
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Lancet Oncol
; 24(8): 913-924, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37414060
5.
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Br J Haematol
; 200(2): 187-196, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36210485
6.
Molecular epidemiology of SARS-CoV-2 variants in circulation in the state of Maranhão, Brazil.
J Med Virol
; 95(9): e29092, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37724346
7.
All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.
Haematologica
; 108(2): 568-580, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36722406
8.
Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period.
Br J Haematol
; 196(3): 649-659, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34622447
9.
Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
Am J Hematol
; 97(6): 731-739, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35253928
10.
Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
Br J Haematol
; 193(1): 181-187, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469083
11.
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
Haematologica
; 106(8): 2054-2065, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33792221
12.
Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.
Ann Hematol
; 100(12): 2997-3005, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34463804
13.
Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure.
Int J Mol Sci
; 22(3)2021 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33498529
14.
Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.
J Immunol
; 200(8): 2581-2591, 2018 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29531171
15.
Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis.
Biol Blood Marrow Transplant
; 23(8): 1269-1275, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28434927
16.
Clinical and Epidemiological Assessment of Children and Adolescents Hospitalized with SARS-CoV-2 in the Pre-Amazon Region.
Biomedicines
; 12(3)2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38540117
17.
The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma.
Hemasphere
; 8(5): e76, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38716147
18.
Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation.
Transplant Cell Ther
; 30(2): 187.e1-187.e12, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38000709
19.
Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations.
Transplant Cell Ther
; 30(2): 213.e1-213.e12, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38042256
20.
EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation.
Bone Marrow Transplant
; 2024 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38521885